PTC299 for Treatment of Advanced Cancer
A Phase 1b Study to Assess the Safety Profile, Pharmacokinetics, and Anti-VEGF Activity of PTC299 in Patients With Advanced Cancer
Sponsor: PTC Therapeutics
A PHASE1 clinical study on Advanced Cancer, this trial is terminated or withdrawn. The trial is conducted by PTC Therapeutics and has accumulated 7 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2019 — Jan 2021 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Jun 2018 — Jun 2019 [monthly]
Suspended PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Suspended PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PTC Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • New York, United States